Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
TORRENT PHARMA ADCOCK INGRAM |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
TORRENT PHARMA Mar-23 |
ADCOCK INGRAM Jun-14 |
TORRENT PHARMA/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
High | Rs | 1,723 | 319 | - | |
Low | Rs | 1,243 | 230 | - | |
Sales per share (Unadj.) | Rs | 284.2 | 94.9 | - | |
Earnings per share (Unadj.) | Rs | 36.8 | -23.9 | - | |
Cash flow per share (Unadj.) | Rs | 57.7 | -19.8 | - | |
Dividends per share (Unadj.) | Rs | 22.00 | 0 | - | |
Avg Dividend yield | % | 1.5 | 0 | - | |
Book value per share (Unadj.) | Rs | 183.1 | 74.5 | - | |
Shares outstanding (eoy) | m | 338.45 | 168.78 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 5.2 | 2.9 | 180.3% | |
Avg P/E ratio | x | 40.3 | -11.5 | -350.9% | |
P/CF ratio (eoy) | x | 25.7 | -13.9 | -185.5% | |
Price / Book Value ratio | x | 8.1 | 3.7 | 219.6% | |
Dividend payout | % | 59.8 | 0 | - | |
Avg Mkt Cap | Rs m | 501,779 | 46,340 | 1,082.8% | |
No. of employees | `000 | NA | 4.3 | 0.0% | |
Total wages/salary | Rs m | 16,777 | 2,908 | 576.8% | |
Avg. sales/employee | Rs Th | 0 | 3,730.7 | - | |
Avg. wages/employee | Rs Th | 0 | 677.5 | - | |
Avg. net profit/employee | Rs Th | 0 | -940.1 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 96,202 | 16,016 | 600.7% | |
Other income | Rs m | 632 | 112 | 563.7% | |
Total revenues | Rs m | 96,834 | 16,128 | 600.4% | |
Gross profit | Rs m | 28,240 | -2,775 | -1,017.5% | |
Depreciation | Rs m | 7,066 | 691 | 1,022.2% | |
Interest | Rs m | 3,334 | 434 | 768.6% | |
Profit before tax | Rs m | 18,472 | -3,788 | -487.6% | |
Minority Interest | Rs m | 0 | -11 | -0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 6,019 | 237 | 2,542.8% | |
Profit after tax | Rs m | 12,452 | -4,036 | -308.6% | |
Gross profit margin | % | 29.4 | -17.3 | -169.4% | |
Effective tax rate | % | 32.6 | -6.2 | -521.5% | |
Net profit margin | % | 12.9 | -25.2 | -51.4% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 53,137 | 11,730 | 453.0% | |
Current liabilities | Rs m | 54,473 | 6,600 | 825.3% | |
Net working cap to sales | % | -1.4 | 32.0 | -4.3% | |
Current ratio | x | 1.0 | 1.8 | 54.9% | |
Inventory Days | Days | 15 | 111 | 14.0% | |
Debtors Days | Days | 7 | 124 | 6.0% | |
Net fixed assets | Rs m | 91,390 | 6,838 | 1,336.6% | |
Share capital | Rs m | 1,692 | 74 | 2,275.8% | |
Net worth | Rs m | 61,981 | 12,571 | 493.1% | |
Long term debt | Rs m | 24,962 | 4,418 | 565.1% | |
Total assets | Rs m | 144,682 | 23,747 | 609.3% | |
Interest coverage | x | 6.5 | -7.7 | -84.6% | |
Debt to equity ratio | x | 0.4 | 0.4 | 114.6% | |
Sales to assets ratio | x | 0.7 | 0.7 | 98.6% | |
Return on assets | % | 10.9 | -15.2 | -71.9% | |
Return on equity | % | 20.1 | -32.1 | -62.6% | |
Return on capital | % | 25.1 | -19.8 | -126.6% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 23,681 | 1,367 | 1,732.3% | |
From Investments | Rs m | -24,153 | -420 | 5,754.0% | |
From Financial Activity | Rs m | 774 | 4,009 | 19.3% | |
Net Cashflow | Rs m | 1,101 | 4,957 | 22.2% |
Compare TORRENT PHARMA With: ACTAVIS (US) MYLAN (US) TEVA PHARMA (Israel)
Compare TORRENT PHARMA With: RPG LIFE SCIENCES MANGALAM DRUGS GLENMARK PHARMA ORTIN LABS SUDARSHAN PHARMA
Asian markets traded lower on Friday tracking overnight losses on Wall Street and inflation data from Japan.